PDAC - PANCREATIC DUCTAL ADENOCARCINOMA
Clinical trials for PDAC - PANCREATIC DUCTAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PDAC - PANCREATIC DUCTAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for PDAC - PANCREATIC DUCTAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill takes on hard-to-treat KRAS cancers in first human trial
Disease control Recruiting nowThis early-phase study tests a new drug called BBO-11818 in adults with advanced lung, pancreatic, or colorectal cancers that have a KRAS mutation. The main goals are to check safety and find the best dose, while also seeing if the drug can shrink tumors. About 387 participants w…
Matched conditions: PDAC - PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated May 01, 2026 15:59 UTC
-
New hope for Hard-to-Treat cancers: targeted combo trial opens
Disease control Recruiting nowThis study tests a new oral drug, TNG462, combined with other treatments for people with pancreatic or non-small cell lung cancer that has lost the MTAP gene and, in some cases, has a RAS mutation. The goal is to find safe doses and see if the combinations shrink tumors. About 18…
Matched conditions: PDAC - PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Tango Therapeutics, Inc. • Aim: Disease control
Last updated May 01, 2026 15:58 UTC
-
New pill aims to keep pancreatic cancer away after surgery
Disease control Recruiting nowThis study tests a new drug, daraxonrasib, to see if it can stop pancreatic cancer from returning after surgery and chemotherapy. About 500 people who have had their tumor removed and finished chemo will either take the drug or just be watched. The goal is to see if the drug help…
Matched conditions: PDAC - PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC
-
New hope for tough pancreatic cancer: targeted nanocells join chemo battle
Disease control Recruiting nowThis study tests whether adding a new targeted treatment (E-EDV-D682/GC) to standard chemotherapy can help people with metastatic pancreatic cancer live longer. The new treatment uses tiny particles called nanocells to deliver a powerful drug directly to cancer cells. About 144 a…
Matched conditions: PDAC - PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Engeneic Pty Limited • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC
-
New smart drug targets tumors, spares healthy cells
Disease control Recruiting nowThis early-phase trial tests a new drug called AVA6103 in people with advanced solid tumors (like pancreatic, stomach, or lung cancer) that have stopped responding to standard treatments. The drug is designed to activate only inside the tumor, potentially killing cancer cells whi…
Matched conditions: PDAC - PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Avacta Life Sciences Ltd • Aim: Disease control
Last updated Apr 29, 2026 15:05 UTC
-
New combo therapy aims to slash deadly leaks after pancreatic surgery
Disease control Recruiting nowThis study tests whether giving a combination of two medicines (hydrocortisone and octreotide) plus using a patch made from the patient's own tissue can lower the risk of major complications after Whipple surgery for pancreatic cancer. The trial includes 400 high-risk patients wh…
Matched conditions: PDAC - PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE4 • Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Disease control
Last updated Apr 29, 2026 15:03 UTC
-
New hope for pancreatic cancer: targeted drug trial launches
Disease control Recruiting nowThis phase 3 trial tests a new drug called daraxonrasib, alone or with standard chemotherapy, for people with metastatic pancreatic cancer that has spread. About 900 adults with a specific RAS gene mutation will be randomly assigned to one of three treatment groups. The study aim…
Matched conditions: PDAC - PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Apr 29, 2026 15:03 UTC
-
Breath of hope: new test could catch pancreatic cancer early
Diagnosis Recruiting nowThis study is testing a new breath test to help detect pancreatic cancer earlier. Pancreatic cancer is often found late because its symptoms are similar to common illnesses. The test looks for tiny molecules in the breath that are made by cancer cells. Researchers will study abou…
Matched conditions: PDAC - PANCREATIC DUCTAL ADENOCARCINOMA
Sponsor: Imperial College London • Aim: Diagnosis
Last updated May 01, 2026 15:59 UTC
-
New app aims to ease the journey for pancreatic cancer patients
Symptom relief Recruiting nowThis study is testing a smartphone app designed to provide information and support to people with pancreatic cancer who are about to start chemotherapy before surgery. About 50 participants will use the app to see if it is helpful and easy to use. The goal is to improve the patie…
Matched conditions: PDAC - PANCREATIC DUCTAL ADENOCARCINOMA
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Apr 29, 2026 15:05 UTC
-
New registry seeks early warning signs for deadly pancreatic cancer
Knowledge-focused Recruiting nowThis study enrolls 5,000 people at high risk for pancreatic cancer to collect blood, pancreatic juice, and medical images over 10 years. Researchers will use this information to develop and test new methods for early detection, including AI-assisted analysis. Participants must be…
Matched conditions: PDAC - PANCREATIC DUCTAL ADENOCARCINOMA
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated May 01, 2026 15:58 UTC
-
Lab-Grown Mini-Tumors could personalize pancreatic cancer care
Knowledge-focused Recruiting nowThis study aims to grow miniature versions of pancreatic tumors (called organoids) from small biopsy samples taken during a routine endoscopic procedure. Researchers will check if these lab-grown organoids match the original tumor's genetics and behavior. If successful, this appr…
Matched conditions: PDAC - PANCREATIC DUCTAL ADENOCARCINOMA
Phase: NA • Sponsor: IHU Strasbourg • Aim: Knowledge-focused
Last updated Apr 30, 2026 15:51 UTC